Navigation Links
Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million
Date:2/20/2009

patent and administrative governmental authorities, competitive factors, technological developments, and costs of developing, producing and selling Zevalin. There is also a risk that even if label expansion of Zevalin is approved, it may not result in a significant market increase for the drug due to the presence of other treatment options, failure to gain market acceptance and other factors. Additionally, the closing of the sale option and receipt of the purchase price assumes that the company will be able to satisfy all of the closing conditions and that Spectrum fulfills its legal obligations to timely deliver the purchase price. Disposition of our interest in Zevalin may not reduce our expenses to the extent as currently projected. You should also review the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: media@ctiseattle.com
    www.CellTherapeutics.com/press_room

    Investors Contact:
    Ed Bell
    T: 206.272.4345
    Lindsey Jesch Logan
    T: 206.272.4347
    F: 206.272.4434
    E: invest@ctiseattle.com
    www.CellTherapeutics.com/investors


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... EVANSTON, Ill. , Dec. 19, 2014 ... to develop novel drugs for diseases of the central ... Ph.D., president and chief executive officer, will present at ... Dr. Riedel,s presentation will take place at 3:00 p.m. ... St. Francis in San Francisco, Calif. ...
(Date:12/19/2014)... 19, 2014 Bina Technologies, Inc. (Bina, ... they have been acquired by Roche (SIX: RO, ROG; ... held company that provides a big data platform for ... data for the academic and translational research markets.  Bina ... will continue to focus on development of their innovative ...
(Date:12/19/2014)... DUBLIN , Dec. 19, 2014 Research ... announced the addition of the "Technology Innovations ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... Innovations in Smart Fabrics" offers a detailed assessment ... Key Findings: 1. ...
(Date:12/19/2014)... 18, 2014 Today, TiFiber, ... pilot production facility and future company headquarters in ... innovative new materials that safely and effectively control ... because of its historic, strong support for manufacturing, ... attract leading edge, technology-based companies such as TiFiber. ...
Breaking Biology Technology:Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3Technology Innovations in Smart Fabrics (Technical Insights) 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 2Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 3Technology Company TiFiber™ to Establish Production Facility in Fort Smith, Arkansas with Support from Local Investors 4
... 2008 - Vol. 299. No. 8: ,Venous Thromboembolism and ... Administration for the Treatment of Cancer-Associated ... believes that,the conclusions of a study published in the ... Medical Association (JAMA) by Bennett, et al, do,not provide ...
... - $28.9 million vs. $19.9 million in Q4 2006 - a 45% ... ... $0.04 in Q4 2006 ... eResearchTechnology,Inc. (eRT), (Nasdaq: ERES ), a leading provider of centralized ECG,eClinical technology, ...
... Be Held Today at 5:00 p.m. ET (22:00 CET), 2007 Financial Highlights, ... Naglazyme net product revenue of $86.2 million, an increase of 85.4 ... $82 million to $84 million, - ... percent over 2006 and toward the upper end of ...
Cached Biology Technology:Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 2Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 3Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 4Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 5Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents 6eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results 2eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results 3eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results 4eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results 5eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results 6eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results 7eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results 8eResearchTechnology Reports Fourth Quarter and Full Year 2007 Results 9BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results 2BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results 3BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results 4BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results 5BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results 6BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results 7BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results 8BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results 9BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results 10BioMarin Announces Fourth Quarter and Full Year 2007 Financial Results 11
(Date:12/17/2014)... 2014 Research and Markets ( ... "Global Chemical Sensor Market 2015-2019" report ... http://photos.prnewswire.com/prnh/20130307/600769 One major trend upcoming ... medical sensors in biomedical applications. Chemical sensors help ... correct diagnosis during surgical procedures. The Global Chemical ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and ... the addition of the "Global Facial Recognition ... http://photos.prnewswire.com/prnh/20130307/600769 ... identification of individuals. Facial recognition system measures the ... nose, jaw edges, mouth, and the distance between ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has ... in India 2015-2019" report to their offering. ... this market is the adoption of multimodal biometric ... characteristic of an individual for verification and identification ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... MASS., January 30, 2008 - The Rockefeller Foundation ... at Tufts University a grant to assess veterinary ... training of Indonesian veterinarians can enhance Indonesias capacity ... animals and people. The $200,000 grant was ...
... Heidelberg, Germany and Rehovot, Israel The European Molecular ... Societies (FEBS) announced Naama Barkai of the Weizman Institute ... of the FEBS/EMBO Women in Science Award. Naama Barkai ... the field of systems biology and the mathematical modelling ...
... CHAMPAIGN, Ill. The continuous fabrication of complex, ... individual nanowires of unlimited length are now possible ... University of Illinois. , Based on the rapid ... has been used to fabricate freestanding nanofibers, stacked ...
Cached Biology News:Cummings School receives Rockefeller Foundation grant 2Cummings School receives Rockefeller Foundation grant 3Systems biologist finds novel solutions to fundamental biological problems 2New process makes nanofibers in complex shapes and unlimited lengths 2
Rat Aortic Endothelial Cells (RAOEC) (>500,000 cells)...
... suitable for use with a wide range ... to water and some of the higher ... of removing water and organic solvents from ... microplates, vials and round bottom flasks; making ...
37-1A9...
... long been a molecule of fascination, ... multiplicity of biologically-active peptides such as ... Hormone (a-MSH) and more. It is ... found in most vertebrates studied, including ...
Biology Products: